Skip to main content

Table 3 Results of the multivariate linear mixed models for the change in fasting glucose level

From: Effect of statins on fasting glucose in non-diabetic individuals: nationwide population-based health examination in Korea

  Coefficient (β) Standard error p
Variables at baseline
 Sex (male) 0.111 0.002 < 0.001
 Age (years) 0.003 < 0.001 < 0.001
 Baseline fasting glucose (mmol/L) − 0.764 0.001 < 0.001
Repeatedly measured variables at NHIS health examination
 Systolic blood pressure (per 10 mmHg) 0.028 < 0.001 < 0.001
 Body mass index (kg/m2) 0.023 < 0.001 < 0.001
 Current smoker 0.021 0.002 < 0.001
Alcohol consumption, frequency per week (times)
 < 1 Ref   
 1–2 0.034 0.002 < 0.001
 3–4 0.094 0.002 < 0.001
 ≥ 5 0.116 0.003 < 0.001
Exercise, days per week (days)
 < 1 Ref   
 1–4 − 0.005 0.001 < 0.001
 ≥ 5 − 0.011 0.002 < 0.001
Household income
 Q1, low Ref   
 Q2, middle − 0.004 0.002 0.015
 Q3, high − 0.011 0.002 < 0.001
Time period from baseline to each health examination (year) 0.035 < 0.001 < 0.001
PDC by any statina 0.093 0.007 < 0.001
PDC by fibrateb 0.022 0.025 0.387
PDC by ezetimibe 0.046 0.045 0.314
anDDD by any statinc 0.119 0.009 < 0.001
  1. Data are derived from the linear mixed models for the change in fasting glucose (mmol/L). These variables were included as fixed-effect variables
  2. PDC proportion of days covered by statins during the time period from baseline to serial health examination (ranged from 0 to 1, treated as a continuous variable)
  3. aValue is the estimated change in fasting glucose when whole time period is covered by statins (PDC = 1)
  4. bBezafibrate, ciprofibrate, etofibrate, fenofibrate, and gemfibrozil
  5. cWhen ‘anDDD by any statin’ were included in the multivariate linear mixed model instead of ‘PDC by any statin’